guly
Forumer storico
salutami schettino.ormai nicox sta facendo l'inchino.
NicOx.... in attesa di.....
- Creatore Discussione DickSIM
- Data di Inizio
salutami schettino.ormai nicox sta facendo l'inchino.
PIZZODIGINO
Pacifico
Detrattori porta sfiga, preparatevi a sparire dalla vergogna (certo non subito, ma in un prossimo futuro).
Pensate che il CEO di Valeant, quindi non uno stupido qualsiasi, ha già messo in preventivo per il secondo semestre 2016, vendite del latanoprostene bunod per 100 milioni di dollari; pensate quanto venderà a pieno regime.
Garufi lavora pieno ritmo anche in estremo oriente.
Il vostro veleno ricadrà su di voi, pentitevi sin che siete in tempo.
Pensate che il CEO di Valeant, quindi non uno stupido qualsiasi, ha già messo in preventivo per il secondo semestre 2016, vendite del latanoprostene bunod per 100 milioni di dollari; pensate quanto venderà a pieno regime.
Garufi lavora pieno ritmo anche in estremo oriente.
Il vostro veleno ricadrà su di voi, pentitevi sin che siete in tempo.
PIZZODIGINO
Pacifico
4 August, 2014 10:33 AM
Esperante, the private, Netherlands-based life science investment company, has announced it has completed the acquisition of Altacor Limited, a specialty ophthalmology company.
Esperante is the investment arm of the C&P Group, a global, privately owned group of life science businesses including Nordic Pharma, a fully-integrated, pan-European pharmaceutical and services company, PolyPeptide Laboratories, a global peptide bulk drug actives producer and Euro-Diagnostica, a European-based immunology in vitro diagnostics business.
Under Esperante’s stewardship Altacor will continue to operate as a specialty ophthalmology company and expects to develop its revenues and market presence significantly by:
& #8226; Expanding its commercial business and specifically the market share of its existing portfolio of Clinitas® products for dry eye, the blepharitis range (Blephakit®) and ocular supplements (Eyebar®) extending its geographic sales reach;
& #8226; Adding to the marketing portfolio by the acquisition and in-licensing of novel ophthalmic therapies and surgical devices;
& #8226; Increasing its marketing portfolio by advancing its current pipeline, which is focused on fast to market, repositioned and orphan products; and
& #8226; Leveraging opportunities within Esperante and its sister companies.
Dean Slagel, Managing Director of Esperante, said, “Esperante has been a minority investor in Altacor for the past 5 years and we are now very excited to be acquiring the entire business to propel Altacor’s promising product and pipeline product portfolio towards an ever more successful and profitable level. We look forward to achieving these objectives in close collaboration with Altacor’s well-proven management team.”
Dr Fran Crawford, CEO of Altacor, added, “We are extremely pleased that Altacor has been acquired by Esperante and that it plans to pursue and expand the company’s existing strategy within a holding group that has a successful track record in building European businesses. I am also delighted that our staff will all remain in position and will continue to drive product sales and pipeline development in the company's chosen markets.”
Esperante, the private, Netherlands-based life science investment company, has announced it has completed the acquisition of Altacor Limited, a specialty ophthalmology company.
Esperante is the investment arm of the C&P Group, a global, privately owned group of life science businesses including Nordic Pharma, a fully-integrated, pan-European pharmaceutical and services company, PolyPeptide Laboratories, a global peptide bulk drug actives producer and Euro-Diagnostica, a European-based immunology in vitro diagnostics business.
Under Esperante’s stewardship Altacor will continue to operate as a specialty ophthalmology company and expects to develop its revenues and market presence significantly by:
& #8226; Expanding its commercial business and specifically the market share of its existing portfolio of Clinitas® products for dry eye, the blepharitis range (Blephakit®) and ocular supplements (Eyebar®) extending its geographic sales reach;
& #8226; Adding to the marketing portfolio by the acquisition and in-licensing of novel ophthalmic therapies and surgical devices;
& #8226; Increasing its marketing portfolio by advancing its current pipeline, which is focused on fast to market, repositioned and orphan products; and
& #8226; Leveraging opportunities within Esperante and its sister companies.
Dean Slagel, Managing Director of Esperante, said, “Esperante has been a minority investor in Altacor for the past 5 years and we are now very excited to be acquiring the entire business to propel Altacor’s promising product and pipeline product portfolio towards an ever more successful and profitable level. We look forward to achieving these objectives in close collaboration with Altacor’s well-proven management team.”
Dr Fran Crawford, CEO of Altacor, added, “We are extremely pleased that Altacor has been acquired by Esperante and that it plans to pursue and expand the company’s existing strategy within a holding group that has a successful track record in building European businesses. I am also delighted that our staff will all remain in position and will continue to drive product sales and pipeline development in the company's chosen markets.”
Zohar
Forumer storico
PIZZODIGINO
Pacifico
Ridi, ridi, che la mamma ha fatto i gnocchi.
PIZZODIGINO
Pacifico
fATTURATO PREVISTO DA VALEANT
PIZZODIGINO
Pacifico
Evidentemente il mercato se ne frega delle previsioni di Valeant e della vendita di Altacor e il prezzo dell'azione scende ai minimi dell'anno. Davvero triste essere azionista Nicox, nemmeno nei giorni di buone notizie si sale.
relavo
Forumer storico
Pizzo, non ho capito di cosa dovrebbero pentirsi quelli che sono scettici su nicox. Il pentimento é la consapevolezza di un errore passato. Quindi io posso senz'altro pentirmi, ma non di non aver fiducia nel pirlotto, bensi' nell'avergliene data a suo tempo a quel tizio dalla inqualificabile condotta.
Che stia in giro per il mondo la cosa non mi stupisce, dato che di soldi ce ne ha fregati parecchi; che stia lavorando é una mera speranza..
Che stia in giro per il mondo la cosa non mi stupisce, dato che di soldi ce ne ha fregati parecchi; che stia lavorando é una mera speranza..
PIZZODIGINO
Pacifico
CAMBRIDGE, England, August 1, 2014 /PRNewswire/ --
Esperante, the private, Netherlands-based life science investment company is pleased to announce that it has completed the acquisition of Altacor Limited, a specialty ophthalmology company. Financial terms were not disclosed.
Esperante is the investment arm of the C&P Group, a global, privately owned group of life science businesses including Nordic Pharma, a fully-integrated, pan-European pharmaceutical and services company, PolyPeptide Laboratories, a global peptide bulk drug actives producer and Euro-Diagnostica, a European-based immunology in vitro diagnostics business.
Under Esperante's stewardship Altacor will continue to operate as a specialty ophthalmology company and expects to grow its revenues and market presence significantly by:
expanding its commercial business and specifically the market share of its existing portfolio of Clinitas® products for dry eye, the blepharitis range (Blephakit®) and ocular supplements (Eyebar®) extending its geographic sales reach;
adding to the marketing portfolio by the acquisition and in-licensing of novel ophthalmic therapies and surgical devices;
adding to the marketing portfolio by advancing its current pipeline which is focused on fast to market, repositioned and orphan products; and
leveraging opportunities within Esperante and its sister companies.
Dean Slagel, Managing Director of Esperante said, "Esperante has been a minority investor in Altacor for the past 5 years and we are now very excited to be acquiring the entire business to propel Altacor's promising product and pipeline product portfolio towards an ever more successful and profitable level. We look forward to achieving these objectives in close collaboration with Altacor's well-proven management team."
Dr Fran Crawford, CEO of Altacor added, "We are extremely pleased that Altacor has been acquired by Esperante and that it plans to pursue and expand the company's existing strategy within a holding group that has a successful track record in building European businesses. I am also delighted that our staff will all remain in position and will continue to drive product sales and pipeline development in the company's chosen markets."
Altacor were advised in this transaction by Longcross Advisers LLP.
Chissà perché non comunicano i dati finanziari dell'acquisizione ?
Esperante, the private, Netherlands-based life science investment company is pleased to announce that it has completed the acquisition of Altacor Limited, a specialty ophthalmology company. Financial terms were not disclosed.
Esperante is the investment arm of the C&P Group, a global, privately owned group of life science businesses including Nordic Pharma, a fully-integrated, pan-European pharmaceutical and services company, PolyPeptide Laboratories, a global peptide bulk drug actives producer and Euro-Diagnostica, a European-based immunology in vitro diagnostics business.
Under Esperante's stewardship Altacor will continue to operate as a specialty ophthalmology company and expects to grow its revenues and market presence significantly by:
expanding its commercial business and specifically the market share of its existing portfolio of Clinitas® products for dry eye, the blepharitis range (Blephakit®) and ocular supplements (Eyebar®) extending its geographic sales reach;
adding to the marketing portfolio by the acquisition and in-licensing of novel ophthalmic therapies and surgical devices;
adding to the marketing portfolio by advancing its current pipeline which is focused on fast to market, repositioned and orphan products; and
leveraging opportunities within Esperante and its sister companies.
Dean Slagel, Managing Director of Esperante said, "Esperante has been a minority investor in Altacor for the past 5 years and we are now very excited to be acquiring the entire business to propel Altacor's promising product and pipeline product portfolio towards an ever more successful and profitable level. We look forward to achieving these objectives in close collaboration with Altacor's well-proven management team."
Dr Fran Crawford, CEO of Altacor added, "We are extremely pleased that Altacor has been acquired by Esperante and that it plans to pursue and expand the company's existing strategy within a holding group that has a successful track record in building European businesses. I am also delighted that our staff will all remain in position and will continue to drive product sales and pipeline development in the company's chosen markets."
Altacor were advised in this transaction by Longcross Advisers LLP.
Chissà perché non comunicano i dati finanziari dell'acquisizione ?
PIZZODIGINO
Pacifico
E' evidente che la pensiamo diversamente su Garufi, ma penso proprio di avere ragione io.
Naturalmente rispetto la tua opinione anche se non la condivido affatto, anche perché allo stato dei fatti, al momento hai ragione tu.
